MAPT and Alzheimer disease: This would be logistically challenging but could be directed to cohorts at known risk of developing AD (e.g. carriers of disease-causing mutations), capitalising on recent progress in identifying novel biomarkers of AD such as CSF tau, β-amyloid assays and amyloid brain imaging, as well as laboratory markers of circadian function (such as melatonin).